Refractory plasma cell neoplasm

This early-stage trial is testing an experimental therapy called LCAR-BCDR, which uses a patient's own immune cells that have been engineered to recognize and attack a protein called BCMA found on myeloma cells. The study aims to see if this treatment is safe and tolerable, and w…

This early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…

This study tested a new experimental drug called GEN3014 (HexaBody-CD38) in people with multiple myeloma and other blood cancers that had returned or become resistant to treatment. The main goal was to check safety and find the right dose. The trial was terminated early, so the f…

This study tested a new CAR-T cell therapy for people with multiple myeloma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells to target cancer cells. The trial was stopped early and only enrolled one person, so we have very limit…

This study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. Th…

This early-phase trial tested a new drug called KRT-232 combined with three standard myeloma drugs (carfilzomib, lenalidomide, and dexamethasone) in 35 patients whose multiple myeloma had returned or stopped responding to treatment. The main goals were to check safety and find th…

This phase 2 study tested a new CAR-T cell therapy called PHE885 in adults with relapsed and refractory multiple myeloma. The therapy targets a protein called BCMA on myeloma cells. The trial aimed to see how many patients responded, but it was terminated early. Results may still…

This early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…

This study tested whether adding an experimental drug (INCB001158) to a standard therapy (daratumumab) could help people with multiple myeloma that returned or didn't respond to prior treatments. The trial enrolled 15 adults who had already tried at least 3 other therapies. The g…

This study tests whether a personalized exercise program (aerobic and resistance training) done before CAR-T therapy can improve physical fitness and quality of life in older adults (60+) with multiple myeloma that has returned or stopped responding to treatment. Twenty participa…